JERUSALEM, Nov 5 (Reuters) - Teva Pharmaceutical

Industries is able to absorb any potential tariffs

imposed by the Trump administration, the company said on

Wednesday as it reported higher-than-expected third-quarter

profit that was boosted by strong sales of its trio of branded

drugs.

Shares in the world's largest generic drugmaker

jumped nearly 20% in New York trading to a new year-high of

$24.23.

Teva said it earned 78 cents per diluted share, excluding

one-time items, in the July to September quarter, up from 69

cents a share a year earlier. Revenue was up 3% in dollar terms

at $4.48 billion.

Analysts had forecast earnings of 67 cents per share

ex-items for the Israel-based company on revenue of $4.34

billion, LSEG I/B/E/S data showed.

Branded drugs - mainly Huntington's disease drug Austedo,

migraine medicine Ajovy and schizophrenia treatment Uzedy -

accounted for $830 million of revenue, a 33% rise over the third

quarter of 2024. Teva is relying on these drugs to drive growth.

They have "allowed us to more consistently grow our level of

revenue and also consistently grow our profitability and

stability, and this also helps us continue to pay down our

debt," CEO Richard Francis told Reuters.

While not yet giving an outlook for 2026, Francis said next

year should see growth in profitability despite the loss of an

expected $1 billion in sales of a generic version of cancer and

blood disorder drug Revlimid due to increased competition.

He noted that Teva will soon file with regulators for a

long-acting version of its schizophrenia medicine olanzapine

that Teva hopes to launch in the second half of next year.

Francis said with nine U.S. manufacturing plants and Austedo

made in the U.S., Teva is well positioned to handle any U.S.

tariffs. Two other innovative drugs are made in Israel but

Francis said "we have the ability to absorb those anyway, within

our supply network".

Teva's sales in the United States rose 12% although European

sales fell 10% in the third quarter.

The group revised down its 2025 revenue estimate to

$16.8-$17.0 billion from $16.8-$17.2 billion and updated its

adjusted EPS forecast to $2.55-$2.65 from $2.50-$2.65.